Home > About Nathalie Scholler
Dr. Nathalie Scholler (née Buonavista) earned an M.D. degree in 1988 from the School of Medicine of Marseille, France, and a PhD in Immunology in 1995 from the University of Aix-Marseille II, France. Her thesis advisor was Dr. Pierre Golstein who discovered CTLA-4 and IL18. CTLA4, the Cytotoxic T-Lymphocyte Antigen 4 (CD152) is a powerful inhibitory molecule that led to the development of Ipilimumab (Yervoy™), an anti-CTLA4 monoclonal antibody with proven clinical benefits and improvements in outcome for patients with psoriasis or cancer.
Dr Scholler completed her post-doctoral training in the Autoimmunity Department of Bristol-Myers Squibb PRI, Seattle, WA in the laboratory of Dr. Peter S. Linsley who first described CTLA-4 ligands. She was then recruited as a Research Scientist in the laboratory of Drs Ingegerd and Karl-Erik Hellström, at the Pacific Northwest Research Institute (PNRI), Seattle, WA. There, she was initiated to Tumor Immunology and discovered that mesothelin is a serum marker for ovarian cancer. The mesothelin ELISA assay that she developed with her team is now commercialized by Fujirebio, Inc. as MesomarkTM.
In March 2003, Dr. Scholler joined the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, to work in the Translational and Outcome Research (TOR) group headed by Dr. Nicole Urban, ScD. She directed the TOR laboratory during four years and created a bead-based assay platform to perform serum diagnostic tests in large populations using site-specific biotinylated recombinant antibodies secreted by yeast (biobodies).
In November 2007, Dr. Scholler joined the University of Pennsylvania as a tenure-track Assistant Professor of Gynecology and Obstetrics. Dr. Scholler's laboratory focuses on investigating the role of innate immunity and B cells in ovarian cancer, and on developing original strategies and reagents for targeted imaging and therapy of cancer. CV